OncRef

Clinical Trial: NCT05340309

Subcutaneous Atezolizumab for the Treatment of Non-small Cell Lung Cancer

Status:

ACTIVE NOT RECRUITING

Phase:

Phase 2

Lead Sponsor:University of Southern California
Information Provided By:University of Southern California
Last Update Posted:2026-01-29

Study Overview

Brief Summary

This phase II trial tests whether subcutaneous atezolizumab can be effectively given at home with medical care provided primarily using telemedicine in patients with non-small cell lung cancer. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This study may help determine if a telemedicine based approach that gives atezolizumab at home using a version of the drug designed for subcutaneous injection under the skin is safe and feasible.

Official Title

A Phase II Study of Subcutaneous Atezolizumab in NSCLC Patients Using a Decentralized Clinical Trial Model

Conditions

Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage IIA Lung Cancer AJCC v8, Stage IIB Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8

Intervention / Treatment

  • Biological: Atezolizumab and Recombinant Human Hyaluronidase
  • Other: Survey Administration

Other Study ID Numbers

  • 2N-21-9
  • NCI-2022-02425
  • 2N-21-9
  • P30CA014089

Start Date (Actual)

2022-12-07

Primary Completion Date (Estimated)

2026-12-31

Study Completion Date (Estimated)

2027-12-31

Enrollment (Actual)

5

Study Type

Interventional

Phase

Phase 2